Tumor-agnostic biomarkers discovered by Nexomic Limited provide universal targets for cancer therapies regardless of tumor origin, enabling broader treatment applications and improved patient outcomes across multiple cancer types.
Tumor-agnostic biomarkers discovered by Nexomic Limited provide universal targets for cancer therapies regardless of tumor origin, enabling broader treatment applications and improved patient outcomes across multiple cancer types.